UNC Hospitals, University of North Carolina at Chapel Hill

Chapel Hill, North Carolina 27599-7600

4 studies enrolling now · 5 studies all time

What they study most

Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Advanced/Metastatic Solid Tumors, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Previously Untreated Relapsed Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Breast Cancer, Refractory Acute Myeloid Leukemia

Studies at this site

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) — Recruiting now
• SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation — Recruiting now
• Study of Biomarker-Based Treatment of Acute Myeloid Leukemia — Recruiting now
• A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors — Stopped early